NASDAQ:CDMO - Avid Bioservices Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $6.07 +0.40 (+7.05 %) (As of 07/20/2018 04:00 PM ET)Previous Close$5.67Today's Range$5.64 - $6.1052-Week Range$2.24 - $6.10Volume1.19 million shsAverage Volume506,591 shsMarket Capitalization$305.75 millionP/E Ratio-12.14Dividend YieldN/ABeta1.99 Company ProfileFinancialsAnalyst RatingsDividend HistoryEarnings HistoryInsider TradesHeadlinesOptions ChainSEC FilingsSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Avid Bioservices, Inc. operates as a contract development and manufacturing organization focusing on the development and cGMP manufacture of biopharmaceutical products derived from mammalian cell culture. It provides a range of process development, and cGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. The company produces monoclonal antibodies and recombinant proteins in batch, fed-batch, and perfusion modes; and provides services, including cGMP clinical and commercial product manufacturing, purification, bulk packaging, stability testing, and regulatory strategy, submission, and support. It also offers various process development activities, including cell line development and optimization, cell culture and feed optimization, analytical methods development, and product characterization. The company was formerly known as Peregrine Pharmaceuticals, Inc. and changed its name to Avid Bioservices, Inc. in January 2018. Avid Bioservices, Inc. is based in Tustin, California. Receive CDMO News and Ratings via Email Sign-up to receive the latest news and ratings for CDMO and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical SymbolNASDAQ:CDMO CUSIPN/A Webwww.avidbio.com Phone714-508-6100 Debt Debt-to-Equity RatioN/A Current Ratio1.79 Quick Ratio0.74 Price-To-Earnings Trailing P/E Ratio-12.14 Forward P/E Ratio-30.35 P/E GrowthN/A Sales & Book Value Annual Sales$53.62 million Price / Sales6.32 Cash FlowN/A Price / CashN/A Book Value$1.26 per share Price / Book4.82 Profitability EPS (Most Recent Fiscal Year)($0.50) Net Income$-28,150,000.00 Net Margins-40.68% Return on Equity-58.67% Return on Assets-31.70% Miscellaneous Employees323 Outstanding Shares55,790,000Market Cap$305.75 Avid Bioservices (NASDAQ:CDMO) Frequently Asked Questions What is Avid Bioservices' stock symbol? Avid Bioservices trades on the NASDAQ under the ticker symbol "CDMO." How often does Avid Bioservices pay dividends? What is the dividend yield for Avid Bioservices? Avid Bioservices declared a dividend on Wednesday, March 7th. Investors of record on Monday, March 19th will be given a dividend of $0.6563 per share on Monday, April 2nd. The ex-dividend date is Friday, March 16th. View Avid Bioservices' Dividend History. When did Avid Bioservices' stock split? How did Avid Bioservices' stock split work? Avid Bioservices's stock reverse split on Monday, July 10th 2017. The 1-7 reverse split was announced on Friday, July 7th 2017. The number of shares owned by shareholders was adjusted after the market closes on Friday, July 7th 2017. An investor that had 100 shares of Avid Bioservices stock prior to the reverse split would have 14 shares after the split. How were Avid Bioservices' earnings last quarter? Avid Bioservices Inc (NASDAQ:CDMO) released its quarterly earnings data on Monday, July, 16th. The biopharmaceutical company reported $0.05 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.15) by $0.20. The biopharmaceutical company had revenue of $6.94 million for the quarter, compared to analyst estimates of $6.51 million. Avid Bioservices had a negative return on equity of 58.67% and a negative net margin of 40.68%. View Avid Bioservices' Earnings History. When is Avid Bioservices' next earnings date? Avid Bioservices is scheduled to release their next quarterly earnings announcement on Monday, September, 10th 2018. View Earnings Estimates for Avid Bioservices. What price target have analysts set for CDMO? 5 equities research analysts have issued 12 month target prices for Avid Bioservices' stock. Their predictions range from $4.00 to $10.00. On average, they anticipate Avid Bioservices' stock price to reach $7.50 in the next year. This suggests a possible upside of 23.6% from the stock's current price. View Analyst Ratings for Avid Bioservices. What is the consensus analysts' recommendation for Avid Bioservices? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Avid Bioservices in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." What are Wall Street analysts saying about Avid Bioservices stock? Here are some recent quotes from research analysts about Avid Bioservices stock: 1. According to Zacks Investment Research, "Avid Bioservices, Inc. is a dedicated contract development and manufacturing organization focused on development and cGMP manufacturing of biopharmaceutical products derived from mammalian cell culture. The company provides process development, high quality cGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. It also offer process development activities, including cell line development and optimization, cell culture and feed optimization, analytical methods development and product characterization. Avid Bioservices Inc., formerly known as Peregrine Pharmaceuticals Inc., is based in TUSTIN, United States. " (7/19/2018) 2. HC Wainwright analysts commented, "Valuation and impediments to achieving price target. We maintain our Buy rating and are increasing our price target to $6 from $5. Our valuation is based on a discounted EBITDA model, which we believe takes into account both the established and anticipated revenue growth of Avid, which is the cornerstone of the company’s business. We assign a 15x (up from 13x) multiple on F2023 EBITDA discounted back at Avid’s WACC of 13%. Our 15x multiple is based on recent CDMO deals in North America, which ranged from 10-15x for EV/LTM EBITDA." (7/17/2018) Are investors shorting Avid Bioservices? Avid Bioservices saw a increase in short interest during the month of June. As of June 29th, there was short interest totalling 3,491,648 shares, an increase of 287.2% from the June 15th total of 901,691 shares. Based on an average trading volume of 1,063,710 shares, the days-to-cover ratio is currently 3.3 days. Currently, 6.4% of the company's stock are sold short. View Avid Bioservices' Current Options Chain. Who are some of Avid Bioservices' key competitors? Some companies that are related to Avid Bioservices include Zai Lab (ZLAB), Athenex (ATNX), Reata Pharmaceuticals (RETA), Esperion Therapeutics (ESPR), Endocyte (ECYT), Tricida (TCDA), Wave Life Sciences (WVE), Intra-Cellular Therapies (ITCI), Vanda Pharmaceuticals (VNDA), Revance Therapeutics (RVNC), Apellis Pharmaceuticals (APLS), OptiNose (OPTN), Flexion Therapeutics (FLXN), Dynavax Technologies (DVAX) and Omeros (OMER). Who are Avid Bioservices' key executives? Avid Bioservices' management team includes the folowing people: Mr. Paul J. Lytle, CFO & Principal Accounting Officer (Age 50)Mr. Mark R. Ziebell J.D., VP, Gen. Counsel & Corp. Sec. (Age 54)Dr. Shelley P. M. Fussey Ph.D., VP of Intellectual Property (Age 52)Ms. Tracy L. Kinjerski, VP of Bus. OperationsMs. Lorna Larson, Sr. Director of HR Has Avid Bioservices been receiving favorable news coverage? News stories about CDMO stock have been trending somewhat positive on Friday, Accern reports. The research firm identifies negative and positive media coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Avid Bioservices earned a media sentiment score of 0.05 on Accern's scale. They also assigned media coverage about the biopharmaceutical company an impact score of 46.26 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the near future. How do I buy shares of Avid Bioservices? Shares of CDMO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Avid Bioservices' stock price today? One share of CDMO stock can currently be purchased for approximately $6.07. How big of a company is Avid Bioservices? Avid Bioservices has a market capitalization of $305.75 million and generates $53.62 million in revenue each year. The biopharmaceutical company earns $-28,150,000.00 in net income (profit) each year or ($0.50) on an earnings per share basis. Avid Bioservices employs 323 workers across the globe. How can I contact Avid Bioservices? Avid Bioservices' mailing address is 2642 Michelle Drive Suite 200, TUSTIN CA, 92780. The biopharmaceutical company can be reached via phone at 714-508-6100 or via email at [email protected] MarketBeat Community Rating for Avid Bioservices (NASDAQ CDMO)Community Ranking: 2.9 out of 5 ( )Outperform Votes: 214 (Vote Outperform)Underperform Votes: 161 (Vote Underperform)Total Votes: 375MarketBeat's community ratings are surveys of what our community members think about Avid Bioservices and other stocks. Vote "Outperform" if you believe CDMO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CDMO will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/20/2018 by MarketBeat.com StaffFeatured Article: What is the Book Value of a Share?